This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Since 1981, when multiple sclerosis (MS) lesions were first visualized in vivo using MRI, understanding of MS disease processes has expanded dramatically. Serial postcontrast imaging shows that MS inflammatory activity is much more frequent than clinical relapses1 and that lesion evolution can take different paths.2 In clinical trials, reduction of new lesion formation predicts clinical efficacy of disease-modifying drugs.3 Despite these advances, key questions remain unanswered: What initiates development of an MS lesion? Which lesions represent severe irreversible tissue damage, and which are likely to remyelinate? What is the most sensitive way to detect new lesions?
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Association of innate immune activation with latent Epstein-Barr virus in active MS lesions
MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T
Magnetic resonance frequency shifts during acute MS lesion formation
Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis